One critical finding was an increased risk of developing a second primary malignancy (SPM) while on long-term lenalidomide maintenance. Patient Considerations
The (often referred to simply as the IFM-05 study) focused on using lenalidomide as a maintenance treatment. IFM_05-May 2022
Lenalidomide was the primary drug used for maintenance in this study. Key Findings: One critical finding was an increased risk of